Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q4 2022 Earnings Conference Call March 1, 2023 4:30 PM ET
Company Participants
Anna Marie Wagner - SVP, Corporate Development
Jason Kelly - Co-Founder & CEO
Mark Dmytruk - CFO
Conference Call Participants
Matthew Sykes - Goldman Sachs
Rahul Sarugaser - Raymond James
Tejas Savant - Morgan Stanley
Steve Mah - Cowen
Madeline - William Blair
Mark Massaro - BTIG
Anna Marie Wagner
Good afternoon. This is Anna Marie Wagner, SVP of Corporate Development at Ginkgo Bioworks. As usual, I'm joined by Jason Kelly, our Co-Founder and CEO; and Mark Dmytruk, our CFO. We thank you for joining us and look forward to providing you with an update on the last quarter and full year '22.
As a reminder, during the presentation today, we'll be making forward-looking statements, which involve risks and uncertainties. Please refer to our filings with the Securities and Exchange Commission to learn more about these risks and uncertainties.
We've got a packed agenda for today, but we'll follow our standard format, providing an update on our financial progress and guidance for the year while also taking the time to dig deeper on our strategic priorities. In particular, as we alluded to in our last call, today we'll be providing more information on the downstream value potential we see at Ginkgo.
We'll enter the Q&A session, and we'll take questions from analysts, investors and the public. You can submit those questions to us in advance via Twitter, #Ginkgoresults or e-mail at investors at ginkgobioworks.com.
All right. Over to you, Jason.
Jason Kelly
Thanks, Anna Marie. We always start with the slide because our mission drives much of our long-term strategy and even many day-to-day decisions in the company. Very simply, we want to make biology easier to engineer at Ginkgo, and we do that by scaling our platform for programming cells.
So how does that work? An easy way to think about Ginkgo is that companies are outsourcing their research to us. In the biopharma industry, that would be called a CRO, a Contract Research Organization. But for traditional CRO, biopharma companies aren't -- they're normally outsourcing simple research work that they really just don't want to do.
Think like running an animal study or synthesizing a chemical, whereas when they're coming to Ginkgo, it's really to outsource work that they can't do themselves internally. They want to access Ginkgo's automation scale, our data, other IP assets, again, that aren't available in-house.